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This editorial refers to ‘Endothelial-dependent vasomo-
tion in a coronary segment treated by the ABSORB ever-
olimus-eluting bioresorbable vascular scaffold system is
related to plaque composition at the time of bioresorption
of the polymer: indirect finding of vascular reparative
therapy?’†, by S. Brugaletta et al., on page 1325
Polymer-based drug-eluting stents (DES) have become the treat-
ment of choice for most patients undergoing percutaneous coron-
ary intervention (PCI). Although these stents efficiently reduce
rates of restenosis and the need for vascular reintervention by
70% compared with bare metal stents (BMS), several risks
closely related to the metallic cage and polymers have recently
been reported. In addition, marked differences exist between
various drug–polymer–device combinations that may translate
into different biological responses. Different vascular healing
responses to the stents could potentially explain differences in
net clinical benefit. Poor endothelialization and coverage of the
stent struts, fibrin deposition, and local inflammatory or hypersen-
sitivity reactions at the site of DES implantation have been asso-
ciated with increased risk of stent thrombosis.1,2 Recent studies
indicated evidence for device-specific responses in the interference
of DES with endothelial function.3 –5
The study of Brugaletta et al.6 brings new hope in cardiology,
taking a new step towards vascular reparative therapy. This study
suggests that in the near future we might be able to treat coronary
lesions using absorbable drug-eluting scaffolds that will provide ad-
equate radial strength to overcome the problem of vascular recoil
and will fix local dissection occurring after lesion dilatation. In add-
ition, they will inhibit smooth muscle cell proliferation and will
finally allow complete recovery of coronary vasomotion. The
latter will hold true not only in the vascular segment adjacent to
the stent, such as at the proximal and distal segments after treat-
ment with BMS,5 but also within the scaffolded segment. This
will be the case after complete stent bioabsorption, providing
optimal healing of the vessel wall.
The authors showed that at 1-year follow-up the vasoreactivity
behaviour of the scaffolded segment did not differ substantially
from the physiological reaction observed distal to the stented
segment. The ability of a coronary segment treated by the
ABSORB bioresorbable vascular scaffold (BVS) device to react
to vasoactive stimuli appears to correlate to the bioabsorption
of the polymeric struts as detected by intravascular imaging tech-
nology. Taken together, these observations indicate that the
stented segment might recover its healthy condition, allowing
physiological vascular function.
These findings are very exciting and are in contrast with the
current interventional therapy, leaving the patients with perman-
ently caged vasculature by metallic prosthesis.7 In a sense, this
therapy is reminiscent of the concept of plaque sealing by coronary
angioplasty introduced several years ago by Bernhard Meier.8 This
was based on the principles that a coronary stenosis subjected to
balloon angioplasty will not progress to a total occlusion later
on, unless it occludes abruptly during or immediately after the
intervention. It was speculated that after disruption with the
balloon, the healing mechanisms with intimal proliferation would
provide a new, smooth, and elastic coat to the ruptured plaque.
This new cap of intimal proliferation could potentially preclude
plaque rupture and protect from coronary thrombosis. This prin-
ciple could, however, not find a broad clinical application because
of the risk of abrupt coronary occlusion induced by local coronary
dissection after balloon angioplasty. In fact, the use of stents in PCI
has rapidly been adopted in the interventional community, limiting
the use of balloon angioplasty for selected lesions only. The intro-
duction of bioabsorbable scaffolds could overcome most of the
limitations of metallic stents.
This promising new technology is, however, still in an early
phase of development. The vascular healing processes are
expected to be very complex and difficult to investigate in vivo,
therefore definitive demonstration of vascular reparative mechan-
isms using this device is expected to be a long process. New inva-
sive imaging techniques such as optical frequency domain imaging
allow precise analysis of strut coverage with microscopic reso-
lution and have the potential to differentiate between fibrin- and
neointimal-covered stent struts (Figure 1).9 In addition, there is
compelling evidence that the healing process could be
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heterogeneous and vary from patient to patient; therefore, larger
studies focused on different patient and lesion characteristics will
be essential before introducing the new technology of BVS in
the clinical arena.
Modern scaffolds have three main components: the metallic
strut, the anti-proliferative drug, and the polymer in which the
drug is immersed allowing for controlled release. Differences in
each one of the main components could explain the clinical differ-
ences seen in randomized studies. The BVS device studied by
Brugaletta et al.6 consists of two components: a polymer backbone
of poly-L-lactide coated with a thin layer of poly-D,L lactide polymer
containing the everolimus, a potent anti-proliferative drug. The
polymer of the ABSORB BVS device is similar to the one used
to cover the ablumilal stent surface of the clinically available metal-
lic DES Nobori (Terumo)10 and Biomatrix (Biosensors),11 that
showed superiority to first-generation DES using durable
polymers. Of particular interest was the relevant reduction in
the risk of stent thrombosis. The vascular reaction to polymers
could, however, differ among patients. Similarly, the way patients
respond to drugs also varies, with some patients requiring a
lower drug dose for equivalent benefit. Everolimus belongs to
the limus family. Similar to sirolimus, zotarolimus, and biolimus,
the biological effects of everolimus are mediated by the intracellu-
lar receptor FK506-binding protein 12. The FK506-binding protein
12–drug complex blocks progression from G1 to S phase in the
cell cycle, inhibiting smooth muscle cell progression and prolifer-
ation. Despite the similarity in the mechanism of action of these
drugs, the presently clinically available stents eluting these drugs
differ in their vascular effects.12 The reported differences include
coronary vasomotion distally to stented segments,3 neointima for-
mation, and stent strut coverage. Such differences could potentially
be explained by a different drug concentration or elution, as well as
Figure 1 Optical frequency domain imaging allows precise analysis of strut coverage with a resolution of 10–20 mm. Selected examples of
stent strut coverage in an experimental model at 3 days (A) and 4 weeks (B) after implantation. Electron microscopy revealed the presence of
fibrin and strut-adherent blood cells at 1 week (C and E) and a complete layer of endothelial cells at 4 weeks (D and F ). In humans, the coverage
of metallic stent struts is often inhomogeneous, presenting covered and uncovered struts in the same stent. Original figure with permission of
C. Templin.9
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by the different polymer used. Recent clinical data indicated that
stents using absorbable polymer are more rapidly endothelialized13
than stents using a non-absorbable polymer, demonstrating super-
ior clinical outcome in reducing the risk of stent thrombosis.14
The plumbing part of PCIs, consisting of re-establishing enough
flow to prevent symptoms even at peak exercise, is important but
should be only a secondary goal.15 The primary goal of interven-
tional coronary treatment should become an improvement in
the prognosis of the patients with coronary artery disease. This
goal can only be achieved by a treatment that, after re-establishing
normal flow conditions by lumen expansion, would allow com-
plete recovery of the vascular function, which at least intuitively
will only be possible by complete disappearance of the scaffold.
Apart from removing the foreign material that may cause a throm-
botic event, bioabsorbable stents have indisputable advantages of
avoiding full metal jackets that can preclude coronary surgery
and they do not interfere with non-invasive diagnostic tools.
Even though preliminary, the reported results seem to indicate
hope for the vascular reparative therapy aimed for.
Conflict of interest: none declared.
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